📊 MBRX Key Takeaways
Is Moleculin Biotech, Inc. (MBRX) a Good Investment?
Moleculin Biotech is a pre-revenue pharmaceutical company with severe operational losses of $12.8M annually and negative operating cash flow of $6.1M quarterly, creating approximately 5 months of remaining cash runway at current burn rates. The company has zero revenue generation, negative ROE (-84.6%) and ROA (-55.0%), and faces imminent capital requirements. The low debt levels and adequate current ratio provide minimal insulation against the structural profitability crisis.
Moleculin Biotech’s fundamentals are very weak: it has no revenue, deeply negative operating and net income, and negative free cash flow with no evidence of commercial scale. While the balance sheet has no meaningful debt and still shows positive equity, the current cash balance appears insufficient relative to annual operating cash burn, making future dilution or financing dependence a major risk.
Moleculin Biotech, Inc. Key Strengths (MBRX)
- Strong balance sheet with zero debt (Debt/Equity: 0.00x) limiting leverage risk
- Adequate liquidity with Current Ratio of 1.38x and Quick Ratio of 1.38x
- Significant cash reserves of $10.3M provide short-term operational flexibility
- Debt-free capital structure reduces financial leverage risk
- Positive stockholders’ equity provides some balance sheet support
- Current ratio above 1.0 indicates near-term obligations are currently covered
MBRX Stock Risks: Moleculin Biotech, Inc. Investment Risks
- Zero revenue generation with no path to profitability evidenced in current fundamentals
- Severe negative cash burn of $6.1M quarterly resulting in ~5-month cash runway
- Persistent substantial operating losses of $7.9M and net losses of $12.8M without revenue offsets
- Probable imminent capital raise necessity at unfavorable terms due to cash depletion
- Zero insider buying activity suggests management confidence absent
- No revenue base means the business is entirely dependent on external financing and pipeline execution
- Large recurring operating and free cash flow losses suggest limited cash runway
- Very weak returns on assets and equity indicate poor current capital efficiency
Key Metrics to Watch
- Cash burn rate trajectory and remaining runway months
- Achievement of clinical or regulatory milestones justifying capital efficiency
- Capital raise announcements and dilution impact on equity holders
- Quarterly operating cash burn versus cash and equivalents
- Any transition from zero revenue to partnership, licensing, or product revenue
Moleculin Biotech, Inc. (MBRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Moleculin Biotech, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MBRX Profit Margin, ROE & Profitability Analysis
MBRX vs Healthcare Sector: How Moleculin Biotech, Inc. Compares
How Moleculin Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Moleculin Biotech, Inc. Stock Overvalued? MBRX Valuation Analysis 2026
Based on fundamental analysis, Moleculin Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Moleculin Biotech, Inc. Balance Sheet: MBRX Debt, Cash & Liquidity
MBRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Moleculin Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-189.14 indicates the company is currently unprofitable.
MBRX Revenue Growth, EPS Growth & YoY Performance
MBRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.9M | $-3.54 |
| Q3 2025 | N/A | -$5.9M | $-0.63 |
| Q2 2025 | N/A | -$4.3M | $-0.49 |
| Q1 2025 | N/A | -$5.0M | $-0.69 |
| Q3 2024 | N/A | -$4.3M | $-2.82 |
| Q2 2024 | N/A | -$4.3M | $-1.70 |
| Q1 2024 | N/A | -$5.0M | $-2.02 |
| Q3 2023 | N/A | -$5.6M | $-0.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Moleculin Biotech, Inc. Dividends, Buybacks & Capital Allocation
MBRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Moleculin Biotech, Inc. (CIK: 0001659617)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBRX
What is the AI rating for MBRX?
Moleculin Biotech, Inc. (MBRX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBRX's key strengths?
Claude: Strong balance sheet with zero debt (Debt/Equity: 0.00x) limiting leverage risk. Adequate liquidity with Current Ratio of 1.38x and Quick Ratio of 1.38x. ChatGPT: Debt-free capital structure reduces financial leverage risk. Positive stockholders’ equity provides some balance sheet support.
What are the risks of investing in MBRX?
Claude: Zero revenue generation with no path to profitability evidenced in current fundamentals. Severe negative cash burn of $6.1M quarterly resulting in ~5-month cash runway. ChatGPT: No revenue base means the business is entirely dependent on external financing and pipeline execution. Large recurring operating and free cash flow losses suggest limited cash runway.
What is MBRX's revenue and growth?
Moleculin Biotech, Inc. reported revenue of $0.0.
Does MBRX pay dividends?
Moleculin Biotech, Inc. does not currently pay dividends.
Where can I find MBRX SEC filings?
Official SEC filings for Moleculin Biotech, Inc. (CIK: 0001659617) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBRX's EPS?
Moleculin Biotech, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MBRX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Moleculin Biotech, Inc. has a D grade with 91% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MBRX stock overvalued or undervalued?
Valuation metrics for MBRX: ROE of -84.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MBRX's AI grade for 2026?
Our dual AI analysis gives Moleculin Biotech, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBRX's free cash flow?
Moleculin Biotech, Inc.'s operating cash flow is $-6.1M, with capital expenditures of $0.0.
How does MBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -84.6% (avg: 15%), current ratio 1.38 (avg: 2).